Tonix Pharmaceuticals stock halted ahead of FDA approval news
Nlight, INC. NASDAQ:LASR Chief Accounting Officer Nias James, reported selling 1,113 shares of common stock on August 14, 2025, at a price of $26.73, for a total value of $29,750. The sale comes as the stock trades near its 52-week high of $28.43, having delivered an impressive 163% return over the past six months. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value.
According to a Form 4 filing with the Securities and Exchange Commission, Nias also acquired 30,000 shares of common stock on August 13, 2025, at no cost, as part of performance-based restricted stock units awarded under the company’s 2018 Equity Incentive Plan.
Following these transactions, Nias directly owns 103,082 shares of Nlight, INC.
In other recent news, Nlight, Inc. reported strong earnings for the second quarter of 2025, surpassing expectations with a 22% increase in revenue. This impressive performance was largely driven by the Aerospace and Defense segment, which exceeded both company guidance and market forecasts. Following these results, several firms, including Stifel, Raymond James, and Needham, raised their price targets for Nlight, reflecting confidence in its future prospects. Stifel increased its target to $26, while Raymond James and Needham both set their targets at $28, maintaining strong buy ratings. Additionally, Nlight announced the appointment of Mark Hartman to its Board of Directors, succeeding Doug Carlisle. In a strategic move, the company granted performance-based restricted stock units to its CEO, Scott Keeney, and CFO, Joseph Corso, contingent on achieving specific stock price targets. These developments highlight Nlight’s robust financial performance and strategic leadership changes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.